Qualix DoT

Qualix DoT is a Barcelona-based R&D company specializing in the pragmatic development of new therapies through drug repurposing and novel delivery systems. Its core mission is to accelerate and de-risk the development of treatments for underserved patient populations by leveraging known compounds. The company operates as a service and project development partner, offering expertise from proof-of-concept generation to regulatory support and IMP supply, with a noted historical focus on bisphosphonates. As a private entity, it appears to be pre-revenue, funded by its parent company Qualix Ventures.

A collaborative platform focused on drug repurposing, innovative formulation/delivery development, and integrated R&D services (including GMP API/IMP supply) to accelerate therapies for unmet needs.

Competes with other drug repurposing specialists, CROs offering development services, and academic tech transfer offices. Its niche in bisphosphonate expertise and integrated IMP supply may differentiate it, but it faces pressure from well-funded AI-driven repurposing platforms and larger biopharma companies with internal repurposing efforts.